Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Gaojun Teng, MD
- 电话号码:+86 13805171500
- 邮箱:gjteng@seu.edu.cn
研究联系人备份
- 姓名:Binyan Zhong, MD
- 电话号码:+86 15850522044
- 邮箱:byzhongir@sina.com
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- The First Affiliated Hospital, Sun Yat-sen University
-
接触:
- Ming Kuang
- 电话号码:020-87755766
- 邮箱:kuangm@mail.sysu.edu.cn
-
接触:
- Zhenwei Peng
- 邮箱:pzhenw@mail.sysu.edu.cn
-
副研究员:
- Wenzhe Fan
-
Guangzhou、Guangdong、中国、510317
- Guangdong Second People's Hospital
-
接触:
- Chengjiang Xiao
- 电话号码:+86 13602808387
- 邮箱:Xxx196610@163.com
-
Guangzhou、Guangdong、中国、510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
接触:
- Liangliang Qiao
- 电话号码:+86 13544539881
- 邮箱:271937316@qq.com
-
Guangzhou、Guangdong、中国、511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
接触:
- Fuxi Huang
- 电话号码:+86 18902299938
- 邮箱:Fuxihuang2006@126.com
-
Guangzhou、Guangdong、中国、524003
- The Second Affiliated Hospital of Guangdong Medical University
-
接触:
- Kangshun Zhu
- 电话号码:+86 13602864242
- 邮箱:Zhksh010@163.com
-
Jiangmen、Guangdong、中国、529030
- Jiangmen Central Hospital
-
接触:
- Yuchuang Liang
- 电话号码:+86 13322888181
- 邮箱:jmlyc@21cn.com
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Wuhan Union Hospital of China
-
接触:
- Xuefeng Kan
- 电话号码:+86 13545874189
- 邮箱:xkliulang1314@163.com
-
-
Hunan
-
Changsha、Hunan、中国、410013
- The Third XIANGYA Hospital of Central South University
-
接触:
- Qi Liang
- 电话号码:+86 137 8731 8180
- 邮箱:csuliangqi10@163.com
-
Changsha、Hunan、中国、410011
- The Second Xiangya Hospital of Central South University
-
接触:
- Yudong Xiao
- 电话号码:+86 136 3740 3027
- 邮箱:xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou、Jiangxi、中国、341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
接触:
- Yusheng Song
- 电话号码:+86 135 7675 2988
- 邮箱:646993126@qq.com
-
Nanchang、Jiangxi、中国、330209
- The First Affiliated Hospital of Nanchang University
-
接触:
- Junhua Ai
- 电话号码:+86 18170936163
- 邮箱:aijh0001@163.com
-
-
Shandong
-
Qingdao、Shandong、中国、266000
- The Affiliated Hospital of Qingdao University
-
接触:
- Song Wang
- 电话号码:+86 18661805592
- 邮箱:derekqyfy@126.com
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
接触:
- Chang Liu
- 电话号码:+86 18980606382
- 邮箱:drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310022
- Zhejiang Cancer Hospital
-
接触:
- Gaojun Teng
- 电话号码:+86 0571 - 88122222
- 邮箱:gjteng@seu.edu.cn
-
接触:
- Binyan Zhong
- 电话号码:+86 15850522044
- 邮箱:byzhongir@sina.com
-
副研究员:
- Jiaping Zheng
-
Jinhua、Zhejiang、中国、321000
- Jinhua Municipal Central Hospital
-
接触:
- Xiaogang Hu
- 电话号码:+86 135 8866 8173
- 邮箱:heartdoctor@163.com
-
Lishui、Zhejiang、中国、323020
- Lishui Central Hospital
-
接触:
- Jiansong Ji
- 电话号码:+86 0578-2285888
- 邮箱:jjstcty@sina.com
-
接触:
- Jianfei Tu
- 邮箱:jianfei1133@163.com
-
Ningbo、Zhejiang、中国、315010
- Ningbo No.2 Hospital
-
接触:
- Yunjie Chen
- 电话号码:+86 13857877137
- 邮箱:a88960317@163.com
-
Ningbo、Zhejiang、中国、315048
- Ningbo Medical Center Lihuili Hospital
-
接触:
- Shengdong Wu
- 电话号码:+86 13567886669
- 邮箱:13567886669@139.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
有源比较器:Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival
大体时间:From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival
大体时间:From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
大体时间:From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
大体时间:Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
大体时间:Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
大体时间:From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
大体时间:Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
大体时间:Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
合作者和调查者
调查人员
- 首席研究员:Gaojun Teng, MD、Zhejiang Cancer Hospital
- 首席研究员:Min Kuang, MD、First Affiliated Hospital, Sun Yat-Sen University
- 首席研究员:Jiansong Ji, MD、The Central Hospital of Lishui City
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- RAINBOW 01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.